Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Bio Products Laboratory Limited (BPL) is a company involved in the manufacture of human blood plasma products, located in Elstree, Hertfordshire, England. It is run as a commercial business and supplies plasma derived products to the National Health Service in the UK as well as to markets in over 45 countries. BPL was a state owned organization and it was part of the U.K. National Health Service for most of its existence. On 1 September 2022, Permira and the Marcucci family acquired BPL and announced that their operations will be merged with another company acquired by the duo, Kedrion.
==== Complex II ==== In Complex II (succinate dehydrogenase or succinate-CoQ reductase; EC 1.3.5.1) additional electrons are delivered into the quinone pool (Q) originating from succinate and transferred (via flavin adenine dinucleotide (FAD)) to Q. Complex II consists of four protein subunits: succinate dehydrogenase (SDHA); succinate dehydrogenase [ubiquinone] iron–sulfur subunit mitochondrial (SDHB); succinate dehydrogenase complex subunit C (SDHC); and succinate dehydrogenase complex subunit D (SDHD). Other electron donors (e.g., fatty acids and glycerol 3-phosphate) also direct electrons into Q (via FAD). Complex II is a parallel electron transport pathway to Complex I, but unlike Complex I, no protons are transported to the intermembrane space in this pathway. Therefore, the pathway through Complex II contributes less energy to the overall electron transport chain process.
=== Sweetpea Golightly === Sweetpea Golightly (Miriam Petche) is a new Pierpoint hire with TikTok and OnlyFans businesses on the side. She is revealed to have had an affair with Rishi, who subscribes to her OnlyFans page. Sweetpea is shown to be a shrewd and competent trader despite her seemingly carefree and social media-obsessed personality. She eventually discovers that a hefty debt Pierpoint issued five years ago to fund their pivot to ESG is reaching maturity, but cannot be paid off since the firm's ESG investments are not making any returns. She reports this to Eric, who tells her to keep it quiet; Harper later overhears Sweetpea telling Yasmin in the bathroom, and uses this information to plan a short of Pierpoint. After Pierpoint is sold to Al-Mi'raj Holdings, Sweetpea leaves the firm to go work for Harper. In series 4, Sweetpea works under Harper at Mostyn Asset Management, but is opposed to Harper's impulsive trading strategy. Sweetpea's explicit photos have leaked online, hurting her job prospects and straining her relationship with her mother. After Harper exits Mostyn's firm and starts her own fund with Eric called SternTao, she brings an apprehensive Sweetpea on board, and the two investigate the shady dealings of payment processing startup Tender, which Harper seeks to short. Sweetpea's investigation leads her on a trip to Accra alongside SternTao trader Kwabena Bannerman to uncover the truth behind Tender's business. Sweetpea is assaulted during the trip by a man possibly sent by Tender, and she and Kwabena have sex.
Significant increases in central MP levels were also observed after just two weeks of supplementation. Furthermore, in patients who had an atypical MP distribution in the eye (i.e., they did not have a high concentration of pigment in the centre of the macula), when supplemented with a meso-zeaxanthin-dominant supplement for 8 weeks, the normal pigment profile was reinstated, whereas this was not the case when patients were supplemented with a formulation lacking meso-zeaxanthin. The main findings from the MOST trials in patients with AMD were published in 2013 and 2015. The series of publications from these trials concluded, "Augmentation of the MP optical density across its spatial profile and enhancements in contrast sensitivity were best achieved after supplementation with a formulation containing high doses of meso-zeaxanthin in combination with lutein and zeaxanthin". Also, the final publication from this work, published in 2015, concluded that, "The inclusion of meso-zeaxanthin in a supplement formulation seems to confer benefits in terms of MP augmentation and in terms of enhanced contrast sensitivity in subjects with early AMD.". In 2016 and 2017, the results of two small clinical trials were published. The first trial, the CREST (Central Retinal Enrichment Supplementation Trials) study involved 105 normal healthy volunteers who underwent a series of complex tests of vision and were supplemented over 12 months.
Cell breakdown products cannot be reused, and are therefore degraded. This gives rise to increased uric acid, a purine breakdown product. The de novo pathway is stimulated due to an excess of PRPP (5-phospho-D-ribosyl-1-pyrophosphate or simply phosphoribosyl-pyrophosphate). It was previously unclear whether the neurological abnormalities in LNS were due to uric acid neurotoxicity or to a relative shortage in "new" purine nucleotides during essential synthesis steps. Genetic mutations affecting the enzymes of the de novo synthesis pathway may possibly contribute to the disease, although these are rare or unknown. Uric acid has been suggested as a possible cause of neurotoxicity but this is unproven. Importantly, evidence suggests that one or more lesions in striatal dopaminergic pathways may be central to the neurological deficits, especially the choreoathetoid dyskinesia and self-mutilation. 6-hydroxydopamine toxicity in rodents may be a useful animal model for the syndrome, although this is not proven. However, the link between dopamine and purine synthesis is a nucleotide called guanosine triphosphate or 'GTP'. The first step of dopamine synthesis is GTP cyclohydrolase, and significantly a deficiency of this step produces a syndrome that has a neuropathology similar to LNS. Thus a lack of HGPRT may produce a nucleotide deficiency (specifically: GTP deficiency) disorder, resulting in dopamine deficiency. Another animal model for LNS has been proposed to arise from oxidative damage, caused by the hyperuricemia accompanying LNS.
Sources: en.wikipedia.org
== Overdose == The incidence of overdose with ezetimibe is rare; subsequently, few data exist on the effects of overdose. However, an acute overdose of ezetimibe is expected to produce an exaggeration of its usual effects, leading to loose stools, abdominal pain, and fatigue.
"Brazil does not grant unilateral exemptions of visitor visas, without reciprocity, to other countries. [...] In attention to the interests of Brazilian citizens, the Brazilian government will be ready to continue negotiating, with the four aforementioned countries, visa waiver agreements on reciprocal bases." — Ministry of Foreign Affairs (Itamaraty). The return of visa charges was received with criticism by some entities linked to the tourism and hospitality sector. For Feliciano Sá Guimarães, director of the Brazilian Center for International Relations, the measure is an obstacle to the development of national tourism and "a vain retrograde nationalist defense". Although the National Confederation of Tourism (Cntur) "did not view it favorably", Wilson Luis Pinto, executive president of the entity, stated that he believed the government took a calculated measure and that the country would not cease to be an option for foreign travelers. "Whoever decided they want to come here will come." Luis Pinto also expressed support for the proposal: "I, as a Brazilian, do not think it is fair to spend months in line and pay a fee to obtain a visa, while an American can buy a ticket and come to Brazil". The government assessed that the resumption of visas would have a low impact on tourism and, according to the Polícia Federal, although in 2019 there were some peaks in the entry of people from North America into Brazil after the visa exemption, this number did not show much increase compared to the period before the measure.
=== NOP cellular signalling partners === Like most G-protein coupled receptors, NOP signals through canonical G proteins upon activation. G proteins are heterotrimeric complexes consisting of α, β, and γ subunits. NOP signals through a variety of Gα subtypes that trigger diverse downstream signaling cascades. NOP coupling to Gαi or Gαo subunits leads to an inhibition of adenylyl cyclase (AC) causing an intracellular decrease in cyclic adenosine monophosphate(cAMP) levels, an important second messenger for many signal transduction pathways. NOP acting through Gαi/o pathways has also been shown to activate Phospholipase A2 (PLA2), thereby initiating Mitogen-activated protein kinase (MAPK) signaling cascades. In contrast to classical OPs, NOP also couples to Pertussis toxin (PTX)-insensitive subtypes Gαz, Gα14, and Gα16, as well as potentially to Gα12 and Gαs. Activation of NOP's canonical β-arrestin pathway causes receptor phosphorylation, internalization, and eventual downregulation and recycling. NOP activation also causes indirect inhibition of opioid receptors MOP and KOP, resulting in anti-opioid activity in certain tissues. Additionally, NOP activation leads to the activation of potassium channels and inhibition of calcium channels which collectively inhibit neuronal firing.
== Early political career (2007-2018) == Bhutto Zardari was appointed as the Chairman of the Pakistan Peoples Party (PPP), on 30 December 2007 at the age of 19, following the assassination of his mother in Rawalpindi earlier that month during a political rally. On this occasion, he recalled his martyred mother, "My mother always said that democracy is the best revenge". In the 2018 Pakistani general election, the PPP, under the leadership of Bilawal Zardari, emerged as the largest party in Sindh and third largest party of Pakistan. The party won 43 seats in the National Assembly, nine more seats than in the 2013 general election. Bhutto Zardari, contested from NA-246 Karachi West-III, Malakand NA-8, as well as NA-200 Larkana. He won from Larkana with 84,426 votes, having lost from two of the other constituencies to candidates for the Imran Khan-founded Pakistan Tehreek-e-Insaf (PTI). Bhutto Zardari claimed that rigging took place before and after the general election, adding that across Pakistan polling agents were expelled from the polling stations and demanding a probe into rigging allegations.
In March 1907 several of Eddy's relatives filed an unsuccessful lawsuit, the "Next Friends suit," against members of Eddy's household, alleging that she was unable to manage her own affairs. Calvin Frye, her long-time personal assistant, was a particular target of the allegations. The New York World's front-page story in October 1906, headline "Mrs. Mary Baker G. Eddy Dying; Footman and Dummy Control Her," said that Eddy was housebound and dying of cancer, that her staff had taken control of her fortune, and that another woman was impersonating her in public. The newspaper persuaded Eddy's family (or "next friends") to file a lawsuit. Several joined the action, including Eddy's biological son, George Glover, and adoptive son, Ebenezer J. Foster Eddy. Eddy was interviewed in her home in August 1907 by the judge and two psychiatrists, who concluded that she was mentally competent. In response to the McClure's and New York World stories, Eddy asked the church in July 1908 to found the Christian Science Monitor as a platform for responsible journalism. It appeared in November that year, with the motto "To injure no man, but to bless all mankind," and went on to win seven Pulitzer Prizes between 1950 and 2002. Eddy died two years later, on the evening of Saturday, December 3, 1910, aged 89. The Mother Church announced at the end of the Sunday morning service that Eddy had "passed from our sight." It said that "the time will come when there will be no more death," but that Christian Scientists "do not look for [Mrs.
Sources: en.wikipedia.org
==== Idiopathic calcinosis cutis ==== Skin calcification that is not linked to a systemic illness or an underlying tissue injury is referred to as idiopathic calcification. Most often, the calcification is restricted to a single general location, yet there has been one case of calcinosis cutis that is exceptionally broad.
The mechanism of SDA is unknown, but in the case of dietary carbohydrates, it has been shown to be strongly related to increases in sympathetic activity. TEF has been described as the energy used in the distribution of nutrients and metabolic processes in the liver. For example, dietary protein produces a high TEF because of the high energy costs associated with processing it, and it has been shown that hepatectomized animal exhibits no signs of TEF. By contrast, the energy costs of the digestion and absorption of food play a much less significant role; indeed, research shows that intravenous injections of nutrients such as glucose or amino acids results in an effect equal to that of oral ingestion of the same nutrients.
"... It has been said, and is still being obstinately repeated by anti-Zionists again and again, that Zionism aims at the creation of an independent "Jewish State". But this is wholly fallacious. The "Jewish State" was never part of the Zionist programme. The "Jewish State" was the title of Herzl's first pamphlet, which had the supreme merit of forcing people to think. This pamphlet was followed by the first Zionist Congress, which accepted the Basle programme—the only programme in existence." At the San Remo conference of 19–26 April 1920, the principal Allied and Associated Powers mandated the creation of a Jewish homeland. Britain officially committed itself to the objective set out in the Balfour Declaration by insisting on its forming the basis of the Mandate for Palestine, which was formally approved by the League of Nations in June 1922. The preamble of the Mandate declared:
Chebulagic acid is a benzopyran tannin and an antioxidant that has many potential uses in medicine. It has been found to be immunosuppressive, hepatoprotective, and a potent alpha-glucosidase inhibitor, a human gut enzyme useful in diabetic studies. It has been shown to be active against Staphylococcus aureus and Candida albicans. It is found in the plants Terminalia chebula, T. citrina and T. catappa. It is formed from geraniin through a glutathione-mediated conversion.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.